Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 1 of 24 pages 1 2 3 > Last ›
HSL2104
Isaacs D, Fitzgerald D.
Seven alternatives to evidence based medicine.
BMJ 1999 Dec 18-25; 319:(7225):1618
http://bmj.bmjjournals.com/cgi/content/full/319/7225/1618
HSL20120
Turner J
A new Rx for drugs
The Toronto Star 1999 Dec 10
HSL20010
Mackinven M
Sales reps losing ground with GPs
New Zealand Doctor News 1999 Dec 9
HSL19870
Moynihan R
A Case of Hype v Hope
The Bulletin 1999 Dec 725-32
http://www.faqs.org/abstracts/News-opinion-and-commentary/A-case-of-hype-v-hope-Power-plays-Howard-back-flip-leaves-Lees-unfazed.html
HSL7948
Business outlook 2000: here we come!
Drug Topics 1999 Dec 6; 143:76-78, 80, 82, 87-88, 90, 93-9
HSL7905
Marshall G.
Common market
Chemist and Druggist 1999 Dec 4; 252:
HSL6869
Lovdahl U, Riska A, Riska E.
Gender display in Scandinavian and American advertising for antidepressants.
Scand J Public Health 1999 Dec; 27:(4):306-10
HSL6919
Lexchin J.
Re: the promotion of Rocmaline (arginine, malic acid) in French-speaking Africa
1999 Dec;
HSL7892
Anon .
R&D success boosts brand name pharmaceuticals
HealthCare Distributors 1999 Dec; 51:12-14, 16, 18-20
HSL7929
Hollenbeak CS.
The effect of generic competition on prescription to over-the-counter switching.
Pharmacoeconomics 1999 Dec; 16:(6):661-8
HSL8105
Jensen MJ.
Development of a searchable Internet database to provide medical information from a pharmaceutical company to health care professionals
ASHP Midyear Clinical Meeting 1999 Dec; 34:
HSL8107
Mehl B.
Pharmaceutical trends: overview of factors responsible for increasing pharmaceutical expenditures
ASHP Midyear Clinical Meeting 1999 Dec; 34:
HSL8108
Stein GC.
Current federal regulatory trends
ASHP Midyear Clinical Meeting 1999 Dec; 34:
HSL12016
Daughton CG, Ternes TA.
Pharmaceuticals and personal care products in the environment: agents of subtle change?
Environ Health Perspect 1999 Dec; 107:
http://www.pubmedcentral.nih.gov.ezlibproxy.unisa.edu.au/articlerender.fcgi?tool=pmcentrez&artid=1566206
HSL6918
Pirisi A.
Patient-directed drug advertising puts pressure on US doctors
Lancet 1999 Nov 27; 354:1887
*news story/United Kingdom/United States/
HSL20008
Jackson A
Getting drug reps under control
Australian Doctor 1999 Nov 2674
HSL19548
Cauchon D
Americans Pay More for Medicines
USA Today 1999 Nov 20
http://www.usatoday.com/life/health/drugs/lhdru066.htm
HSL2151
Wynia MK, Latham SR, Kao AC, Berg JW, Emanuel LL.
Medical professionalism in society.
N Engl J Med 1999 Nov 18; 341:(21):1612-6
http://content.nejm.org/cgi/content/extract/341/21/1612
HSL6877
Price VH.
Authors' conflicts of interest: a disclosure and editors' reply.
N Engl J Med 1999 Nov 18; 341:(21):1618-9
HSL7928
Conlan MF.
Bill goes after Flo as battle for Medicare Rx benefit heats up
Drug Topics 1999 Nov 15; 143:71
HSL20146
Mant A
On the (mis)information superhighway
Medical Observer 1999 Nov 12
HSL6859
Johansen HK, Gotzsche PC.
Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.
JAMA 1999 Nov 10; 282:(18):1752-9
http://jama.ama-assn.org/cgi/content/full/282/18/1752
HSL6917
Rennie D.
Fair conduct and fair reporting of clinical trials.
JAMA 1999 Nov 10; 282:(18):1766-8
http://jama.ama-assn.org/cgi/content/full/282/18/1766
HSL20176
MacKinven M
DTC advertising isn't a black and white issue
Australian Doctor 1999 Nov 1019
HSL6916
Pakenham-Walsh N, Eddleston M, Kaur M.
Developing world needs access to low cost pharmaceutical information from reliable sources.
BMJ 1999 Nov 6; 319:(7219):1265
http://bmj.com/cgi/content/full/319/7219/1265, http://bmj.com/cgi/reprint/319/7219/1265.pdf
HSL5318
Bell RA, Kravitz RL, Wilkes MS.
Direct-to-consumer prescription drug advertising and the public.
J Gen Intern Med 1999 Nov 01; 14:(11):651-7
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.1999.01049.x
HSL8098
With 100 days to Y2K, some health care settings remained vulnerable
American Journal of Health System Pharmacy 1999 Nov 1; 56:2181
HSL1841
Jackson C, Mcguire T, Dommers E, Nyst P.
A GP prescribing educational intervention involving a medication panel.
Aust Fam Physician 1999 Nov; 28:(11):1191-5
HSL1842
Slawson DC, Shaughnessy AF.
Teaching information mastery: creating informed consumers of medical information.
J Am Board Fam Pract 1999 Nov-Dec; 12:(6):444-9
HSL6860
Kjaergard LL, Nikolova D, Gluud C.
Randomized clinical trials in hepatology: predictors of quality.
Hepatology 1999 Nov; 30:(5):1134-8
http://www3.interscience.wiley.com/cgi-bin/abstract/106596467/ABSTRACT?CRETRY=1&SRETRY=0
HSL6912
Charlish P.
DTC advertising encourages consumers to talk about drugs
Scrip Magazine 1999 Nov9-10
www.pjbpubs.co.uk/scrip/scrhome.html
HSL6913
Law J.
Preparing to advertising directly to the European consumer
Scrip Magazine 1999 Nov; (84):6-7
www.pjbpubs.co.uk/scrip/scrhome.html
HSL6915
Redelmeier DA.
Drug dependence in a journal club.
ACP J Club 1999 Nov-Dec; 131:(3):A13-4
HSL7731
Allen J.
Surgical internet at a glance: healthcentral and drKoop.
Am J Surg. 1999 Nov; 178:(5):359
http://linkinghub.elsevier.com/retrieve/pii/S0002-9610(99)00214-7
HSL7922
Hallahan M, Madell R.
Rx branding: brand new culture
Pharmaceutical Executive 1999 Nov; 19:98-100, 102, 104
HSL7923
Wechsler J.
DTC dilemma
Pharmaceutical Executive 1999 Nov; 19:22, 24, 26-27
HSL7924
Pal S.
Generic industry market review
US Pharmacist 1999 Nov; 19:(24):9, 14-15, 22-23, 30, 34
HSL7946
Beavers N.
Generic industry abuzz over Medicare, exclusivity proposals
Drug Topics 1999 Nov; 143:
HSL6841
Bosch X.
Spain investigates "bribery" of doctors.
Lancet 1999 Oct 30; 354:(9189):1537
HSL6876
Phillips SG, Carey LA.
Whose article is it anyway?
Lancet 1999 Oct 30; 354:(9189):1563
HSL18023
Ferriman A.
Selling drugs to consumers
BMJ 1999 Oct 30; 319:(7218):1208
http://www.bmj.com/cgi/content/full/319/7218/1208?view=long&pmid=10541537
HSL20123
Reguly E
Battle brews over Canadian drug ads
The Globe and Mail 1999 Oct 30B2
HSL6839
Armstrong K, Schwartz JS, Asch DA.
Direct sale of sildenafil (Viagra) to consumers over the Internet.
N Engl J Med 1999 Oct 28; 341:(18):1389-92
http://content.nejm.org/cgi/content/extract/341/18/1389
HSL6852
Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL.
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
JAMA 1999 Oct 20; 282:(15):1453-7
http://jama.ama-assn.org/cgi/content/full/282/15/1453
HSL6911
Krimsky S.
Conflict of interest and cost-effectiveness analysis.
JAMA 1999 Oct 20; 282:(15):1474-5
http://jama.ama-assn.org/cgi/content/full/282/15/1474
HSL7904
van den Hoogen H, Hooijman G, Meulepas M.
Bottom up approach of local pharmacotherapeutic consultations involving pharmacists and general practitioners
Pharmaceutisch Weekblad 1999 Oct 15; 134:1400-1404
HSL20014
Jacobs A
Reasons for not seeing drug representatives: But doctors do see them: 'freebies' seem disproportionately important
BMJ 1999 Oct 9; 319:(7215):1002
http://www.ncbi.nlm.nih.gov/pubmed/10576839
HSL6909
Mansfield P.
Debate: drug advertising
Australian Doctor 1999 Oct 864
HSL6910
McLean DL.
Debate: drug advertising
Australian Doctor 1999 Oct 864
HSL20170
McLean DL
Debate: drug advertising: Yes
Australian Doctor 1999 Oct 8
HSL20171
Mansfield P
Debate: drug advertising: No
Australian Doctor 1999 Oct 864
HSL6906
Alper PR.
Direct-to-consumer advertising: education or anathema?
JAMA 1999 Oct 6; 282:(13):1226-7
http://jama.ama-assn.org/cgi/content/full/282/13/1226
HSL6907
Holmer AF.
Direct-to-consumer advertising: Education or anathema? [reply]
JAMA 1999 Oct 6; 282:(13):1227-1228
HSL6908
Rosner F, Kark P, Packer S, Bennett A, Berger J.
Direct-to-consumer advertising: education or anathema?
JAMA 1999 Oct 6; 282:(13):1227
HSL8102
New community pharmacy foundation to benefit from lawsuits against drug companies
American Journal of Health System Pharmacy 1999 Oct 1; 56:1912, 1915
HSL1032
Lexchin J.
Don't bite the hand that feeds you.
West J Med 1999 Oct; 171:(4):238-9
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=10578675
HSL6853
Glassman PA, Hunter-Hayes J, Nakamura T.
Pharmaceutical advertising revenue and physician organizations: how much is too much?
West J Med 1999 Oct; 171:(4):234-8
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=10578674
HSL7921
Bowles R, Howell P, Ott T, Heller S.
Medicare Rx benefits: implications for the pharmaceutical industry
Pharmaceutical Executive 1999 Oct; 19:62, 64, 66, 68, 70
HSL7951
Settlement funds: distribution decided in price-fixing case
America's Pharmacist 1999 Oct; 121:20-21
HSL7964
Wechsler J.
Controversy over prescription drug advertising stimulates policy changes
Formulary 1999 Oct; 34:878-879
HSL7966
Schwartz RM.
TV ad campaign fights Clinton Rx plan
American Druggist 1999 Oct; 216:15
HSL2031
Drug-company decision to end cancer trial.
Lancet 1999 Sep 25; 354:(9184):1045
http://linkinghub.elsevier.com/retrieve/pii/S0140673699003207
HSL20175
Parnell K
Barrage of wrong information
Australian Doctor 1999 Sep 2427
HSL6905
Rhame FS.
Implications of "market baskets," a pharmaceutical marketing practice.
JAMA 1999 Sep 22-29; 282:(12):1134
http://jama.ama-assn.org/cgi/content/full/282/12/1134
HSL6849
Elston MJ.
Following the rules in marketing.
CMAJ 1999 Sep 21; 161:(6):685
http://www.cma.ca/cmaj/vol-161/issue-6/letters-6.htm
HSL8100
FDA finalizes guidance on DTC broadcast ads
American Journal of Health System Pharmacy 1999 Sep 15; 56:1815
HSL8101
Congress explores limits on Internet pharmacy
American Journal of Health System Pharmacy 1999 Sep 15; 56:1812
HSL7932
Newton P.
Promotion vs regulation
Chemist and Druggist 1999 Sep 11; 27
HSL19549
Prescription Drug Pricing in the United States: Drug Companies Profit at the Expense of Older Americans
U.S. House of Representatives. 1999 Sep 11
HSL19938
Bisset K, Parnell K
Ad comments off target
Australian Medicine 1999 Sep 6
HSL19939
Hui L, Hayman M
S4 advertising no help
Australian Medicine 1999 Sep 66
HSL3687
Dyer C.
Incontinence campaign tests limits of advertising rules.
BMJ 1999 Sep 4; 319:(7210):591
http://bmj.bmjjournals.com/cgi/content/full/319/7210/591
HSL1895
The fine line between education and marketing..
Proj Inf Perspect 1999 Sep 01; (28):1-3
HSL200
Vandenbroucke JP, Helmerhorst FM, Rosendaal FR.
Competing interests and controversy about third generation oral contraceptives: BMJ readers should know whose words they read.
BMJ 1999 Sep; 319:(7213):795-6
http://bmj.bmjjournals.com/cgi/content/full/320/7231/381/a
HSL7729
Mani MK.
A Faustian bargain.
Natl Med J India 1999 Sep-Oct; 12:(5):244-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10613011&dopt=Abstract
HSL7926
Koberstein W.
Media Mix: Rx marketers blend consumer & medical campaigns
Pharmaceutical-Executive 1999 Sep; 19:46-47
HSL7927
Koberstein W.
Media Mix masters: PE's annual agency roundtable
Pharmaceutical Executive 1999 Sep; 19:50-84
HSL7933
Morris L.
DTC & Rx costs: circumstantial case
Pharmaceutical Executive 1999 Sep; 19:20
HSL7953
Lyftingsmo S.
Survey on labeling 1999
International Pharmacy Journal 1999 Sep-Oct; 13:127
HSL7978
Colchamiro R.
Generic drugs: patent wars rage on
American Druggist 1999 Sep; 216:33-34, 36-38, 40, 42
HSL6855
Hafeez A, Mirza Z.
Responses from pharmaceutical companies to doctors' requests for more drug information in Pakistan: postal survey.
BMJ 1999 Aug 28; 319:(7209):547
http://www.bmj.com/cgi/content/full/319/7209/547
HSL2096
Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA.
Users' guides to the medical literature: XIX .Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group.
JAMA 1999 Aug 25; 282:(8):771-8
http://jama.ama-assn.org/cgi/content/full/282/8/771
HSL6904
Glaser T.
Yes . . . but what solutions?
BMJ 1999 Aug 23; 319:(7208):525
http://bmj.com/cgi/eletters/319/7208/525/a#4335
HSL6903
Dunea G.
Fancy drugs for worried folks.
BMJ 1999 Aug 21; 319:(7208):525A
HSL6902
Vermeulen L.
Clarification and amplification
BMJ 1999 Aug 20; 319:(7208):525
http://bmj.com/cgi/eletters/319/7208/525/a#4335
HSL6882
Ruffmann R.
Funding of clinical research.
Lancet 1999 Aug 14; 354:(9178):602
HSL2013
Silverstein K.
Millions for Viagra, Pennies for the Poor
The Toronto Star 1999 Aug 13
HSL16738
Wolfe S
Promotion of Off-Label Uses of Drugs
USA Today 1999 Aug 9
HSL6901
Cottle M.
Selling shyness: how doctors and drug companies created the “social phobia” epidemic
New Republic 1999 Aug 2
HSL8104
Sellers JA.
Medicare drug benefit.
Am J Health Syst Pharm 1999 Aug 1; 56:(15):1503
http://www.ajhp.org/cgi/reprint/56/15/1503
HSL6850
Ferguson RP, Rhim E, Belizaire W, Egede L, Carter K, Lansdale T.
Encounters with pharmaceutical sales representatives among practicing internists.
Am J Med 1999 Aug; 107:(2):149-52
http://linkinghub.elsevier.com/retrieve/pii/S0002934399001928
HSL7958
Schwartz H.
Unlikely support
Pharmaceutical Executive 1999 Aug; 19:26, 28
HSL7960
Smith D.
Does your DTC message pass the consumer litmus test?
Pharmaceutical-Executive 1999 Aug; 19:9
HSL8091
Rankin K.
Generic manufacturers look to Washington for change
Pharmacy Times 1999 Aug; 66:79-80, 82
HSL20269
Chren M-M
Interactions between physicians and drug company representatives
Am J Med 1999 Aug; 107:(2):182-3
http://www.ncbi.nlm.nih.gov/pubmed/10460053
HSL14669
Riggert E.
Drug firms' 'gifts' to GPs
The Advertiser 1999 Jul 26
HSL19940
Hansen K
Are medical publications selling out?
Australian Medicine 1999 July 1910-11
HSL6854
Griffith D.
Reasons for not seeing drug representatives.
BMJ 1999 Jul 10; 319:(7202):69-70
http://www.bmj.com/cgi/content/full/319/7202/69
HSL6862
Larkin M.
Whose article is it anyway?
Lancet 1999 Jul 10; 354:(9173):136
HSL6900
Barents Group LLC
Factors affecting the growth of prescription drug expenditures
Washington, D.C: National Institute for Health Care Management Research and Educational Foundation 1999 Jul 9
Page 1 of 24 pages 1 2 3 > Last ›
